Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:51:56.646Z.
Calculation as of: 2026-10-06T14:51:56.646Z.
Quote observation: 2026-10-06T14:50:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Electra Therapeutics Inc.
Market Cap
$202.37M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.39M
Operating Cash Flow Yield
N/A
TTM Avg
41.63%
3Y Avg
41.53%
5Y Avg
35.39%
Market Cap
$211.96M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.50M
Operating Cash Flow Yield
2.77%
TTM Avg
2.54%
3Y Avg
2.69%
5Y Avg
2.62%
Market Cap
$191.04M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$190.35M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$217.70M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$223.78M
Operating Cash Flow Yield
N/A
TTM Avg
14.77%
3Y Avg
14.64%
5Y Avg
14.64%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $202.37M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $210.39M | N/A | 41.63% | 41.53% | 35.39% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $211.96M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $213.22M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.50M | 2.77% | 2.54% | 2.69% | 2.62% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $191.04M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $190.35M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $217.70M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $223.78M | N/A | 14.77% | 14.64% | 14.64% |
| Journey Medical Corporation (DERM)vs › | $178.89M | N/A | 11.12% | 9.89% | 9.89% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
